Get started

Health

ELI LILLY has at least +50% upside from here.Eli Lilly (LLY) has been trading within a 5-year Channel Up and last week closed below its 1W MA50 (blue trend-line) for the first time since the week of March 06 2023. Despite the bearish pressure of this Bearish Leg since July 15 2024, that last 1W MA50 closing was the previous Higher Low at the bottom of the Channel Up. The 1W RSI is on a similar level (just below 40.00) with all previous 4 major bottoms and the common characteristic of all was that the stock broke below the 1W MA50 but managed to keep clear and hold the 1W MA100 (green trend-line), practically the most important Support level of the market. If you want a confirmed buy entry, you might want to wait for yet another Bullish Cross on the 1W MACD (as it happened on all previous bottoms), otherwise this buy opportunity is good to go for at least +58% from the bottom (minimum rise among those 4 Bullish Legs). Our Target is $1135. ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NYSE:LLYLong
by TradingShot
2
JOHNSON & JOHNSON Excellent confirmed sell signalJohnson & Johnson (JNJ) gave us the most optimal buy entry on our last call (April 17, see chart below) and easily hit our 157.50 Target: Having been rejected early in September exactly at the top (Lower Highs trend-line) of the 2-year Channel Down and now establishing price action below its 1D MA50 (blue trend-line), this is a confirmed sell signal and the start of the Channel's 5th Bearish Leg. The RSI Lower Highs are common on all previous Channel tops. Our Target is 141.00, which is on the Internal Lower Lows trend-line (formed by the last 2 Lower Lows) and still above the 1.236 Fibonacci extension. ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NYSE:JNJShort
by TradingShot
ELI LILLY Always a solid buy below its 1D MA50.Eli Lilly (LLY) broke on Friday below its 1D MA50 (blue trend-line) for the first time since August 09. As the stock trades within a long-term Channel Up since the March 01 2023 bottom, every time the price was below the 1D MA50, it didn't stay for long, thus providing the most effective buy entry. Even though it could dip some more as with July's decline (only such case though out of 6 corrections), as long as the 1D MA200 (orange trend-line) holds, we expect the Channel Up to be extended. The initial Higher Highs were closer to the 1.5 Fibonacci Channel extension, the last one however was exactly on the 1.0 Fib. As a result, we will take a more conservative Target on that trend-line, thus turning bullish now and aiming at $1100 by the end of the year. ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NYSE:LLYLong
by TradingShot
UNITED HEALTH forming a bottom.United Health (UNH) gave an excellent dip buy opportunity last time (March 29, see chart below), with the price even breaking above the long-term Resistance Zone eventually: The price has since entered a Channel Up pattern with the price now below its 1D MA50 (blue trend-line), having already topped and attempting to form a new Higher Low at the bottom of the pattern. Like the previous one in June, this bottoming process can take another 3 weeks, so we will time it accordingly and target 675.00 (+21.00% rise, similar to both previous Bullish Legs). ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NYSE:UNHLong
by TradingShot
CVS - CVS Health: If the stock drops a few points, I'll be buyiIf the stock drops a few points, I'll be buying very heavily... CVS and WBA are in the same sector. And both have been decimated. CVS, however, is doing better. And they're paying a dividend. Target, at least +10%. Trading at 70% below estimate of its fair value Earnings are forecast to grow 9% per year Earnings grew by 140% over the past year DIVIDEND = Pays a high and reliable dividend of 4.75% Trading at good value compared to peers and industry Analysts in good agreement that stock price will rise by 20%
NYSE:CVSLong
by Maximus20000
Investors Await Q1 ReportKey arguments in support of the idea. ▪ UNH stock has come under pressure from a series of adverse events, though Q1 earnings may improve investor sentiment regarding further UNH business growth potential. ▪ A good moment for buying, both fundamentally and technically. Investment Thesis UnitedHealth Group (UNH) engages in the provision of health insurance, software, and related consulting services. UNH is the largest provider of healthcare plans in the US. In Early 2024, UNH’s Stock Came Under Pressure from Several Adversities at Once . First, it is a cyberattack on Change Healthcare services, that led to a temporary freeze on payments from medical organizations. At the time of finalizing this report, UnitedHealth informed that services were restored, and that it did not expect big implications for financial results. However, market participants fear a one-time negative impact on profitability in Q1 2024. Shortly after the cyberattack, it was reported that the US Department of Justice had initiated an antitrust investigation for examining the strength of relationship between UnitedHealth’s insurance and medical business divisions. The impact of the investigation is uncertain, and we do not believe it to influence the stock in the short term. Investors Were Disappointed by CMS’ Final Decision on Medicare Advantage (MA) Payment Rates. On April 2, MA plan rate rises for 2025 compared to 2024 became finally known. The payout rate remained at the proposed level of 3.7% y/y, disappointing investors looking for a bigger increase. This caused a negative market reaction: UNH, the largest player, ended the April 2 trading with a 9.3% drop. Some other major stocks reacted that day accordingly: HUM (-13.4%), CVS (-7.2%), ELV (-3.3%). The worsened MA business revenue expectations for 2025 are already reflected in prices. However, the Optum segment’s organic growth (OptumHealth, OptumInsight, and OptumRx) remains a strong point of the Company and may support its Q1 2024 results that will be released on April 16. Expectations for Q1 Report. We think that investors will be focused on the guidance for 2024. Management’s confirmation or improvement of the existing guidance could dispel investor worries. Besides, we expect a detailed commentary on the impact of the cyberattack and the MA rate decision on financial results. Now Is a Good Time to Buy. The P/E NTM ratio has decreased to 15.8, which is lower than the Company’s all-time average of 18.8. The RSI has dropped below 30 points, signaling a likely reversal. We consider UNH shares’ current weakness as a good opportunity to buy, assuming that (1) the impact of the approved MA 2025 rate is already reflected in prices, (2) the cyberattack will have a one-time insignificant implication for UNH, and (3) there is still a high demand in the MA market, and UNH remains the largest and growing provider of healthcare plans. The target price for UNH over a 2-month horizon is $495, which corresponds to P/E NTM of 18. We recommend Buying and setting a Stop Loss at $415.
NYSE:UNH
by FreedomHolding
Gaxos Acquires Rights to AI-enabled TechnologyGaxos.ai Inc., ( NASDAQ:GXAI ) a pioneering force in artificial intelligence (AI) applications, has announced a significant strategic move to bolster its presence in the health and wellness sector. The acquisition of rights to AI-enabled technology from the top biohacking app, Ultiself, marks a pivotal moment in Gaxos' journey towards revolutionizing the human-AI relationship. Unlocking Enhanced Customization and User Experience: The integration of Ultiself's proprietary technology into Gaxos Health's ( NASDAQ:GXAI ) product offering signifies a leap forward in personalized health solutions. By harnessing the power of AI, Gaxos aims to deliver unparalleled customization and efficiency to meet the evolving demands of modern consumers. This strategic move is poised to accelerate the development of Gaxos Health's AI-enabled application, paving the way for innovative diet, nutrition, and tracking capabilities. CEO's Vision for Innovation: Vadim Mats, CEO of Gaxos.AI, underscores the significance of securing the rights to this cutting-edge technology. With a focus on delivering value to customers and stakeholders, Mats envisions a future where Gaxos ( NASDAQ:GXAI ) redefines the human-AI relationship across diverse sectors, including health, wellness, and gaming. The commitment to leveraging AI solutions underscores Gaxos' dedication to addressing critical aspects of human well-being and entertainment. Collaborative Integration Process: The integration process between Gaxos ( NASDAQ:GXAI ) and Ultiself teams has commenced immediately, highlighting a collaborative approach to ensure a seamless transition. With both teams working in tandem, Gaxos endeavors to leverage Ultiself's technology to its fullest potential, driving innovation and enhancing user experiences. The synergy between Gaxos and Ultiself sets the stage for groundbreaking advancements in AI-enabled health solutions. Gaxos.ai's Vision for the Future: Gaxos.AI ( NASDAQ:GXAI ) isn't merely developing applications; it's pioneering a paradigm shift in the human-AI landscape. With a steadfast commitment to redefining health, longevity, and entertainment through AI solutions, Gaxos sets its sights on transformative innovation. The expansion into health and wellness represents a strategic pivot towards addressing fundamental human needs and shaping the future of AI-driven technologies. Technical Outlook Prior to the news, ( NASDAQ:GXAI ) stock surged by a whopping 50.38% trading above its 200-day Moving Average with a Relative Strength Index (RSI) of 63.54.
NASDAQ:GXAILong
by DEXWireNews
Hologic: Holding Above 200-week SMA Inside of a Cup with HandleHologic is currently Consolidating within the potential handle of a Bullish Cup with Handle pattern and is holding above the 200-week Simple Moving Average. If this pattern plays out successfully, the measured move target would take HOLX up to around $118. n addition to the technical pattern, HOLX seems to be improving its balance sheet on an annual basis, consistently increasing Assets while decreasing Liabilities and Debts. Overall, this stock seems like a stronger stock within the health sector.
NASDAQ:HOLXLong
by RizeSenpai
Analysis of CVS Stock Trends: A Parabolic Turn on the HorizonFashionable Analysis of CVS Stock Trends: A Parabolic Turn on the Horizon Introduction: In the realm of financial fashion, CVS stock is set to make a stylish entrance with a parabolic turn, showcasing a strong formation on the 4D timeframe. This trend is marked by the elegant falling wedge pattern and the chic double bottom overlapping patterns, following a dose of impactful news related to drug patents. Technical Analysis - CVS Stock: The 4D timeframe reveals the graceful formation of a falling wedge pattern, signifying a poised parabolic turn in CVS stock. This pattern, complemented by double bottom overlapping formations, is a testament to the stock's resilience, especially against the backdrop of recent drug patent news highlighted on CNBC ( www.cnbc.com ). Price Targets and Corrections: The first take profit target stands confidently at $76.78, offering investors a lucrative moment to capitalize on the impending parabolic turn. Following this peak, a correction to approximately $71.07 is expected, providing a brief pause for market adjustments. Strategic Entry and Second Take Profit Target: Wise investors can strategically enter the market around $71.07, anticipating a second take profit target at a stylish $82.44. This forecasted move aligns with the rhythm of the stock's recent patterns, emphasizing the importance of timing in the world of financial fashion. Historical Elegance: Tracing CVS stock's journey since April 2019, a period marking the middle of the pandemic, unveils a remarkable rally. The stock gracefully formed a strong falling wedge pattern on the 4Day timeframe, echoing a sense of resilience and adaptability. The rally continued, reaching its peak around February 01, 2022, before gracefully correcting until October 25, 2023. Future Projections: As the music of the market plays on, further continuation of this trend is expected. The forecasted trajectory anticipates a new level of elegance for CVS stock by the end of 2024, reaching a poised $106.97. This future projection exudes confidence and sets the stage for CVS to make a bold statement in the financial fashion world. In the intricate dance of stocks and patterns, CVS is poised to captivate investors with its upcoming parabolic turn and a tale of resilience, gracefully crafted on the canvas of market trends.
NYSE:CVSLong
by wikitrades
UNITED HEALTH Buy signal to complete the Cup pattern.United Health is on a green (1w) candle despite the general market sell-off. This is technically due to the longer term pattern which is shaping up to be a Cup/ Arc, that remains to be seen if at the end of it will give a Handle. Trading Plan: 1. Buy on the current market price. Targets: 1. 553.00 (bottom of Resistance Zone 1 which was initially formed on April 11th 2022). Tips: 1. The MACD (1d) is rising with a Bullish Cross last seen in July and despite being bullish over 0.00, it is still underpriced. Please like, follow and comment!!
NYSE:UNHLong
by TradingBrokersView
ABBV Long-term buy confirmedAbbVie Inc. (ABBV) opened today much higher than the 1D MA200 (orange trend-line), which is a strong enough buy signal on its own. Coupled however with the fact that the rebound was achieved on the Higher Lows trend-line that started way back on the COVID (March 23 2020) market bottom, it makes it an even stronger one. In fact on a 2-3 month basis, this is the most optimal buy signal an investor can have. As you see on this 1D chart, the stock had 4 Higher High touches during that period and the only time the price broke above the Channel Up was on February 16 2022 the break-out of which peaked on April 08 2022. With the help of the Fibonacci Channel levels we can see why the price stopped where it stopped. In fact we also see the important role of the median (Fib 0.5). Based on the above, we expect a new Higher high around the $180.00 price mark. ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NYSE:ABBVLong
by TradingShot
1
CVS | FINALLY Time to Enter | LONGCVS Health Corporation provides health services in the United States. The company's Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services. It serves employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups, and expatriates. Its Pharmacy Services segment offers pharmacy benefit management solutions, including plan design and administration, formulary management, retail pharmacy network management, mail order pharmacy, specialty pharmacy and infusion, clinical, and disease and medical spend management services. It serves employers, insurance companies, unions, government employee groups, health plans, prescription drug plans, Medicaid managed care plans, plans offered on public health insurance and private health insurance exchanges, other sponsors of health benefit plans, and individuals. This segment operates retail specialty pharmacy stores; and specialty mail-order, mail-order dispensing, and compounding pharmacies, as well as branches for infusion and enteral nutrition services. The company's Retail/LTC segment sells prescription and over-the-counter drugs, consumer health and beauty products, and personal care products; and provides health care services through its MinuteClinic walk-in medical clinics. This segment also distributes prescription drugs; and provides related pharmacy consulting and other ancillary services to care facilities and other care settings. As of December 31, 2021, it operated approximately 9,900 retail locations and 1,200 MinuteClinic locations, as well as online retail pharmacy websites, LTC pharmacies, and onsite pharmacies. The company was formerly known as CVS Caremark Corporation and changed its name to CVS Health Corporation in September 2014. CVS Health Corporation was founded in 1963 and is headquartered in Woonsocket, Rhode Island.
NYSE:CVSLong
by DivergenceSeeker
2